| 姓名 | 离任职务 | 离任时间 | 原定任期 到期日 | 离任原 因 | 是否继续在上 市公司及其下 | 是否存在未履 行完毕的公开 | | --- | --- | --- | --- | --- | --- | --- | | | | | | | 属子公司任职 | 承诺 | | 徐春玲 | 副总裁 | 2025 年 12 | 2027 年 8 | 到龄退 | 否 | 否 | | | | 月 30 日 | 月 15 日 | 休 | | | （二）离任对公司的影响 根据《中华人民共和国公司法》和《公司章程》等有关规定，徐春玲女士的 辞职自公司董事会收到辞职报告时生效。徐春玲女士的离任不会影响公司的正常 运作及经营管理。徐春玲女士持有公司股份 50,000 股，不存在未履行完毕的公 开承诺，其将继续严格遵守《上海证券交易所上市公司自律监管指引第 15 号—— 股东及董事、高级管理人员减持股份》《公司董事、高级管理人员持股及变动管 理办法》等法律法规的相关规定。 浙江康恩贝制药股份有限公司 关于高级管理人员离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600572 证券简称：康恩贝 公告编号：临 2025-079 浙江康恩贝制药股份有限公司 关于选举董事长、副董事长等事项的公告 2025 年 12 月 31 日 附件：人员简历 1、应徐颉，中国籍，男，1973 年生，沈阳药科大学本科学历，副主任药师，中共 党员。曾任浙江英特药业有限责任公司总经理、董事长，浙江英特集团股份有限公司总 经理、董事长、党委书记。现任浙江省国际贸易集团有限公司副总经理、党委委员，浙 江康恩贝制药股份有限公司第十一届董事会董事长、党委书记。现未持有本公司股份。 2、金军丽，中国籍，女，1980 年生，浙江财经大学本科学历，会计师，中共党员。 曾任浙江省国际贸易集团有限公司审计部副总经理、经营管理部总经理、办公室主任、 董事会秘书、职工董事，浙江海正集团有限公司监事，浙江海正药业股份有限公司监事。 现任浙江康恩贝制药股份有限公司第十一届董事会副董事长、党委副书记。现未持有本 公司股份。 1 2025 年 12 月 30 日，浙江康恩贝制药股份有 ...

证券代码：600572 证券简称：康恩贝 公告编号：临 2025-078 浙江康恩贝制药股份有限公司 第十一届董事会第十四次（临时）会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 浙江康恩贝制药股份有限公司(以下简称"公司")第十一届董事会第十四次（临时） 会议于 2025 年 12 月 30 日以通讯方式召开。会议通知和延期召开会议通知分别于 2025 年 12 月 17 日和 12 月 18 日以书面、电子邮件方式送达各董事。会议应参加审议表决董 事 9 人，实际参加审议表决董事 9 人。会议的召开符合《公司法》《公司章程》的规定。 会议经全体董事审议表决，通过决议如下： 一、审议通过《关于选举公司董事长、副董事长的议案》。表决情况：同意 9 票， 反对 0 票，弃权 0 票。 选举应徐颉先生任公司第十一届董事会董事长、金军丽女士任公司第十一届董事会 副董事长，任期自本次董事会审议通过之日起至第十一届董事会任期届满之日止。 二、审议通过《关于选举代表公司执行公司事务董事的议案》。表决情况：同意 9 票，反对 ...

人民财讯12月30日电，康恩贝（600572）12月30日公告，12月30日，公司召开第十一届董事会第十四次 (临时)会议，审议通过《关于选举公司董事长、副董事长的议案》《关于选举代表公司执行公司事务董 事的议案》等议案。全体董事一致同意选举应徐颉任公司第十一届董事会董事长、金军丽任公司第十一 届董事会副董事长；同意选举应徐颉为代表公司执行公司事务的董事，并担任公司法定代表人。以上人 员任期均自本次董事会审议通过之日起至第十一届董事会任期届满之日止。 ...

康恩贝12月30日公告，公司董事会当天收到公司副总裁徐春玲递交的书面辞职报告，因到龄退休原因， 徐春玲向公司董事会申请辞去副总裁职务。徐春玲辞去副总裁职务后，将不再担任公司任何职务。 ...

Core Viewpoint - The company is focusing on the application of AI technology to transform into an intelligent-driven pharmaceutical enterprise, having established a dedicated AI task force and identified over 20 AI application scenarios [1] Group 1: AI Technology Application - The company has completed the identification of over 20 AI application scenarios, exploring uses in academic promotion, drug development, talent training, and intelligent comparison of packaging versions [1] - The company is collaborating with professional institutions and introducing AI drug research platforms and traditional Chinese medicine models to enhance its drug discovery process [1] Group 2: Innovation and Research - The company aims to accelerate the new drug discovery process by leveraging its high-level research platform to assist in new drug screening and the identification of effective substances [1] - The focus on AI in drug development is intended to address challenges in new drug creation and further enhance the company's innovation capabilities [1]

Core Viewpoint - Kang En Bei (600572) has received approval from the National Medical Products Administration for two specifications of the inhalation solution of Salbutamol Hydrochloride, indicating a significant advancement in its product portfolio and potential market opportunities in the respiratory medication sector [1] Group 1: Company Developments - Kang En Bei's wholly-owned subsidiary, Zhejiang Jinhua Kang En Bei Biopharmaceutical Co., Ltd., has been granted drug registration certificates for Salbutamol Hydrochloride inhalation solution with approval numbers H20256396 and H20256397 [1] - The inhalation solution was first launched in Japan in 2002 under the brand name "Meptin" [1] Group 2: Product Information - The approved specifications for the inhalation solution are 0.5ml:50μg and 0.3ml:30μg, which are set to be marketed in China in 2023 and 2024 respectively [1] - The primary indications for the inhalation solution include alleviating symptoms of bronchial asthma, chronic bronchitis, and emphysema, which are diseases characterized by airflow limitation [1]

Group 1 - In December, several leading pharmaceutical companies experienced significant executive changes, including Guoyao Holdings, BeiGene, and Zhendong Pharmaceutical [1][2] - Kexin Pharmaceutical announced the election of Li Hongfu as the chairman of its fourth board of directors on December 1 [1] - Kang En Bei reported that Jiang Yi resigned from multiple positions, including chairman, on December 6 due to work adjustments [1] Group 2 - WuXi AppTec appointed Tian Feng as the CEO and executive director, effective December 29, 2025 [2] - Alibaba Health announced the resignation of Zhu Shunyan as non-executive director and chairman, with current CEO Shen Difan taking over as chairman [2] - Sangfor Technologies reported the resignation of core technical personnel, Weng Zhibing, from all positions in its wholly-owned subsidiary on December 16 [2] Group 3 - Zhendong Pharmaceutical announced that Yang Lianmin resigned from his positions due to reaching retirement age on December 18 [2] - BeiGene appointed Dr. Wang Lai as president and global head of R&D, effective December 19 [2] - Guoyao Holdings announced Jin Bin as the new chairman on December 19, following the resignation of Zhao Bingxiang [2] Group 4 - Shijiazhuang Pharmaceutical Group reported that Zhang Cuilong stepped down from multiple roles, while Cai Lei was appointed as vice chairman and CEO on December 19 [3] - Weichuang Bio announced the appointment of Li Jianxun as general manager, while Chairman Lu Xianping stepped down from the general manager role on December 23 [3] - Shandong Pharmaceutical Glass reported that Chairman Hu Yonggang resigned from all positions due to age, with General Manager Zhang Jun taking over the chairman's responsibilities on December 24 [3]

证券简称：康恩贝 证券代码：600572 编号：2025-077 浙江康恩贝制药股份有限公司 关于子公司盐酸丙卡特罗吸入溶液 获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其 内容的真实性、准确性和完整性承担法律责任。 上市许可持有人：金华康恩贝 批准文号：国药准字 H20256396、国药准字 H20256397 证书编号：2025S03931、2025S03932 近日，浙江康恩贝制药股份有限公司（以下简称"公司"）全资子公司浙江金华康恩 贝生物制药有限公司（以下简称"金华康恩贝"）收到国家药品监督管理局（以下简称" 国家药监局"）核准签发的两个规格的盐酸丙卡特罗吸入溶液《药品注册证书》，现将相关 情况公告如下： 一、药品的基本情况 药品名称：盐酸丙卡特罗吸入溶液 剂型：吸入制剂 规格：按 C16H22N2O3·HCl·½H2O 计 （1）0.3ml:30μg （2）0.5ml:50μg 注册分类：化学药品 3 类 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 二、药品 ...

Core Viewpoint - Kang En Bei (600572.SH) has received approval from the National Medical Products Administration for two specifications of the inhalation solution of salbutamol, which is primarily used to alleviate symptoms of bronchial asthma, chronic bronchitis, and emphysema, among other airflow-restricted diseases [1] Group 1 - The company’s wholly-owned subsidiary, Zhejiang Jinhua Kang En Bei Biopharmaceutical Co., Ltd., is responsible for the newly approved medication [1] - The inhalation solution is aimed at treating respiratory conditions that involve airflow limitation [1]